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Abstract
Background: Neisseria meningitidis (Nm) is a pathogen of multiple serogroups that is highly prevalent in many
populations. Serogroups associated with invasive meningococcal disease (IMD) in Canada, for example, include A, B,
C, W-135, X and Y. IMD is a rare but serious outcome of Nm infection, and can be prevented with vaccines that target
certain serogroups. This has stimulated the development of dynamic models to evaluate vaccine impact. However,
these models typically aggregate the various Nm serogroups into a small number of combined groups, instead of
modelling each serogroup individually. The impact of aggregation on dynamic Nm model predictions is poorly
understood. Our objective was to explore the impact of aggregation on dynamic model predictions.
Methods: We developed two age-structured agent-based models–a 2-strain model and a 4-strain model–to
simulate vaccination programs in the Canadian setting. The 2-strain model was used to explore two different
groupings: C, versus all other serogroups combined; and B, versus all other serogroups combined. The 4-strain
model used the four groupings: C, B, Neisseria lactamica, versus all other serogroups combined. We compared the
predicted impact of monovalent C vaccine, quadrivalent ACWY vaccine (MCV-4), and monovalent B vaccine
(4CMenB) on the prevalence of serogroup carriage under these different models.
Results: The 2-strain and 4-strain models predicted similar overall impacts of vaccines on carriage prevalence,
especially with respect to the vaccine-targeted serogroups. However, there were some significant quantitative
and qualitative differences. Declines in vaccine-targeted serogroups were more rapid in the 2-strain model than
the 4-strain model, for both the C and the 4CMenB vaccines. Sustained oscillations, and evidence for multiple
attractors (i.e., different types of dynamics for the same model parameters but different initial conditions), occurred in
the 4-strain model but not the 2-strain model. Strain replacement was also more pronounced in the 4-strain model, on
account of the 4-strain model spreading prevalence more thinly across groups and thus enhancing competitive
interactions.
Conclusions: Simplifying assumptions like aggregation of serogroups can have significant impacts on dynamic
model predictions. Modellers should carefully weigh the advantages and disadvantages of aggregation when
formulating models for multi-strain pathogens.
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Background
Neisseria meningitidis (Nm) is a significant concern to
public health. Prevalence of carriage varies between 5
and 10 % of the population [1]. Six main serogroups im-
pact public health: A, B, C, W-135, X, and Y [1]. In
Canada, serogroup B is most prevalent, although C, X,
and Y are part of the ecological landscape as well, and
are targeted by immunization programs at the time of
writing [2–4]. Incidence of invasive meningococcal dis-
ease (IMD) in Canada ranges from 0.4 to 0.7 per
100,000 individuals [2], which is small compared to the
disease burden in some countries, such as the “meningitis
belt” of sub-Saharan Africa.
Nm infection is usually commensal: the pathogen typ-
ically colonizes the mucosal layer of the nasopharynx
asymptomatically. Nm can be spread through the aerosol
route, including coughing and sneezing, but also through
close contact [2]. Therefore, closed environments, such
as schools, households, and workplaces yield conditions
conducive to transmission [5–10]. IMD incidence tends
to be highest in children under 2 years of age, while Nm
carriage tends to be highest in adolescent teenagers and
young adults (17–21 years of age).
IMD symptoms develop when the colony penetrates
the mucosal layer into the bloodstream, leading eventually
to meningitis septicaemia [11]. Targeting the meninges
and causing IMD, N. meningitidis can cause permanent
neurological damage or fatality if not treated promptly.
Many who survive IMD suffer loss of limbs or hearing.
Determinants of individual susceptibility to IMD are not
well understood.
There are several routes to natural immunity to Neis-
seria meningitis. After being infected with any serogroup
of Nm, many individuals produce anti-bodies that prevent
invasion by all serogroups of the pathogen, reducing the
risk of becoming infected, although the duration of im-
munity is unknown, and probably relatively short [12].
Another route to transient Nm immunity is contracting
Neisseria lactamica (Nl), a commensal pathogen. Though
it is known that Nl colonizes the same loci as N. menin-
gitidis, the mechanism and nature of the immunity is
under study and currently not well known, though
ideas of creating a vaccine using Nl have been proposed
[13, 14]. N. lactamica colonization induces Immunoglobin
A and Immunoglobin G antibody production, preventing
recolonization for at least 24 weeks [15]. Though the
mechanism is not clear, it is known that an immunological
response to Nl causes an immunological response to Nm.
N. meningitidis and N. lactamica compete with one
another for the same loci in the nasopharynx, as do the
various N. meningitidis serogroups. If one pathogen is
introduced to a host while the other has already colo-
nized, the invading pathogen will not easily colonize due
to competition for nutrients or adhesion [13].
Currently, vaccines reduce carriage and IMD rates in
vaccinated individuals, and also unvaccinated individuals
through herd immunity [16]. Previous polysaccharide
vaccines were relatively ineffective, and could cause side
effects [17]. However, in 2001 a conjugate vaccine that tar-
gets serogroup C was recommended for use in Canada for
infants and children [18]. IMD incidence attributable to
serogroup C was greatly reduced amongst the age groups
that were vaccinated, as well as those that were not vacci-
nated [18]. However, with the reduced incidence of IMD
attributable to serogroup C (and presumably, carriage as
well), a small gap has been left in the ecological niche:
there is less asymptomatic carriage of serogroup C in the
nasopharyx, which, in principle, means more opportun-
ities for other serogroups to colonize. This has caused
some concern over potential vaccine-induced strain re-
placement [19]. We speculate that this ‘ecological’
strain replacement should be even stronger for vaccines
against very common serogroups, such as serogroup B,
if serogroups compete for space in the nasopharynx.
In 2007, Canada’s National Advisory Committee on
Immunization recommended a quadrivalent conjugate Nm
vaccine, meningococcal conjugate vaccine (MCV-4), that
immunizes against serogroups A, C, W-135, and Y. A rou-
tine vaccine program was recommended for adolescent in-
dividuals in areas that local epidemiology warranted the
prevention of the outbreaks, while high risk individuals
were also recommended for vaccination [20].
Serogroup B causes significant IMD in many countries,
since it dominates the ecological landscape of its environ-
ment [21]. Vaccines against serogroup B have been diffi-
cult to produce because the capsular polysaccharides for
serogroup B are too similar to human neural antigens
[22, 23]. Previous attempts required up to 20 different
types of the antigen, PorA [24]. Though there have
been difficulties, a vaccine has been developed using
only four different components, 4CMenB [25]. With
the use of 4CMenB in addition to MCV-4, it has been
predicted that more than three quarters of the various
Nm serogroups in Europe can be covered [26]. It is also
predicted that 4CMenB can be used to target certain
strains of serogroup X, which no vaccine is currently
able to cover [27]. 4CMenB is one step closer to a uni-
versal vaccine for Nm, since the components found in
the vaccine can also be found in all other capsule
groups, thus 4CMenB may have an impact on other
serogroups, although perhaps less efficaciously than the
MCV-4 vaccine.
Previous models describing the impact of immunization
on population health have aggregated all Nm serogroups
into only two or three groups [28–31]. Some models ag-
gregated all serogroups of Nm while modeling the effects
of Nl [28]. Other models have analyzed a single vaccine
applied to different age categories [2, 30, 31], while some
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models compare vaccine types [2]. These models can
produce valuable insights, and aggregating serogroups
is a necessary model simplification. However, aggregat-
ing serogroups can also influence model projections be-
cause the ecological effects of serogroup structure and
serogroup interactions cannot be fully accounted for
[32, 33], and it is known that multi-strain models can
produce qualitatively different dynamics from single-
strain models [34–38]. To our knowledge no research
has directly compared the results of few-strain versus
many-strain dynamic Nm models.
Here we develop, analyse and compare two age-
structured, agent-based transmission models. The first
model aggregates all serogroups into one of two categories
while the second model aggregates all serogroups into one
of four categories. Our objective is to compare the pre-
dicted impacts of monovalent C, monovalent B, and
quadrivalent CAWY vaccines on Nm carriage using the
two models, in order to learn more about potential
biases introduced by using few-strain models to model
multi-strain infectious diseases such as Nm.
Methods
4-strain model
Our 4-strain model utilizes four groupings: (1) ser-
ogroup B, (2) serogroup C, (3) serogroups A, W-135, X,
Y, 29e, and ‘ungroupable’ (UG) serogroups, and (4) Neis-
seria lactamica. We include Neisseria lactamica since it
competes for the same loci on the nasopharynx as Neisseria
meningitidis serogroups [13]. Serogroups A, W-135, X, and
Y are rare in Canada but 29e and the ungroupable ser-
ogroups are more prevalent. Hence, in the 4-strain model,
serogroup B, serogroup C, and Nl form their own compart-
ments, whereas other serogroups are lumped into the same
compartment with one or more other serogroups.
The population is divided into annual age cohorts: <1
year old, 1 year olds, 2 year olds, 3 year olds, …, 99 year
olds. Individual ages are updated monthly, moving the
individual into the next age cohort after 12 simulated
months. Individuals are removed each month according
to all-cause, age-specific mortality rates [39] (Table S1 in
Additional file 1). Individuals are born into the popula-
tion at a constant rate, η, each month. A fine age struc-
ture enables comparing scenarios that distinguish
between vaccinating at 12 months versus 24 months, for
instance. However, for model calibration, broader age
categories of 0–4, 5–9, 10–14, 15–19, and 20+ years of
age were used, because 5-year age intervals are used in
most available Nm carriage prevalence data as well as in
the available contact data [40].
Disease transmission includes a baseline transmission
rate specific to each age group and strain, βi,k, that is
modified by an age specific contact matrix, Ci,j [40]. The
contact matrix includes both the physical and non-
physical contact of individuals as Nm is transmitted
through aerosol means. Newborns are susceptible to all
serogroups of Nm and to Nl. The probability per time-
step that an individual of age j is infected by serogroup k
is given by
p Ii;k
  ¼ 1−Y100
j¼0 1−
βi;kCi;jI j;k
Nj
  
ð1Þ
where Ii,k,is the number of individuals of age i infected
with strain k (carrying the strain asymptomatically), and
Nj is the number of individuals of age, j. Upon infection,
individuals become a carrier of the kth serogroup.
No individual can be infected with more than one ser-
ogroup simultaneously. After the duration of carriage,
τ1k, has elapsed the individual becomes naturally im-
mune to serogroup k that infected them, for a short
duration τ2k sampled from a gamma distribution. We
assume that the average duration of carriage is the same
for all ages and Nm serogroups. The average duration of
carriage for Nl is also assumed to be the same for all ages,
but differs from the average duration of carriage of Nm
[13, 41]. While natural immunity to serogroup k, individ-
uals also have some partial cross-protection against other
serogroups, so that the probability per timestep that an in-
dividual of age j is infected by some other serogroup k is
given by
p Ii;k
  ¼ 1−Y100
i¼0 1−
βi;kCi;jI j;k
Nj
 
1−σ lð Þ
 
ð2Þ
where, 0 < σl <1 is the cross-immunity conferred by pre-
vious infection by serogroup l ≠ k. Cross-immunity lasts
the same period of time as strain-specific immunity. De-
tails on all parameter values appear in Additional file 1:
Table S1.
2-strain model
The 2-strain model aggregates Nl and Nm serogroups,
but it uses two groupings instead of four. The first ver-
sion of the 2-strain model uses the groups: C versus Nl
and all other Nm serogroups aggregated (A/B/W-135/X/
Y/29e/UG/Nl). The second version uses the groups B
versus Nl and all other Nm serogroups aggregated (A/C/
W-135/X/Y/29e/UG/Nl). The first version is used to
simulate the impact of monovalent C vaccine and com-
pare it to the simulated impact of the monovalent C vac-
cine using the 4-strain model. Likewise, the second
version is used to simulate the impact of monovalent B
vaccine and compare it to the simulated impact using
the 4-strain model. The 2-strain model is otherwise
identical to the 4-strain model. In both versions, the
duration of carriage and immunity was assumed to be
the duration of Nm and was set by sampling from a
gamma distribution.
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Parameterization and uncertainty analysis
We used Canadian demographic and epidemiologic data
to parameterize the model. The baseline natural history
and demographic parameters were taken directly from
the literature, while the baseline transmission rates βi,k
were calibrated so that the age-stratified serogroup-
specific carriage prevalence in the model matched the
empirical data, within specified ranges of acceptability
(Figure S1 in Additional file 1 and Table S2 in Additional
file 1 for the 4-strain model) [2, 3]. In particular, initial
values of βi,k were assumed for each simulation; every 100
simulated years, the code checked whether the modelled
age-specific carriage prevalence was within the range of
empirical acceptability based on seroprevalence data, for
all of the ranges (20 for the 4-strain model, 10 for the
2-strain model); if so, those calibrated values of βi,k
were used in the simulation, and if not, the values of
βi,k were adjusted upward or downward as appropriate
and the process was repeated for another 100 simula-
tion years until the target ranges were attained.
The degree of cross-protection is not well known, so
we used values from an in-vitro cross-reactivity study
[42] (see Table S1 in Additional file 1 for baseline par-
ameter values; see Tables S2, S3, S4 for the average βi,k
values in Additional file 1). 50 realizations for each vac-
cine scenario were thereby produced, each through this
calibration procedure. 50 realizations were used because
this was found to be a sufficient number of realizations
to produce representative averages of the (stochastic)
agent-based model, at baseline parameter values. All re-
sults reported are the averages and standard deviations
of the 50 realizations except where otherwise noted.
The calibration targets for the 4-strain model were ob-
tained by adding the carriage prevalence of the constituent
serogroups (Table S5 in Additional file 1). Similarly, the
calibration of the 2-strain model, the acceptability ranges
for prevalence of carriage were different for each age
group and serogroup (Tables S6, S7 in Additional file 1).
In the case of the 4-strain model, a significant number
of parameter sets yielded dynamics where serogroup
prevalence oscillated over time, indicating the likely
presence of multiple attractors. These parameter sets
were not included in the baseline analysis, but are dis-
cussed separately at the end of the Results section.
Vaccine scenarios and assumptions
We explored nine vaccination scenarios with the 4-
strain model (Table 1) and six scenarios with the 2-
strain model (Table 2). Vaccination begins at t = 150
years (which provides enough “burn-in” to discard tran-
sients) and is continued for 75 years (tend = 225 years).
For the 4-strain model, scenarios 1–3 use a monova-
lent C vaccine, scenarios 4–6 use a quadrivalent ACWY
vaccine (MCV-4), and scenarios 7–9 use a monovalent
B vaccine (4CMenB). For the 2-strain model, scenarios
1–3 use a monovalent C vaccine and scenarios 4–6 use
the 4CMenB. Coverage of toddlers and infants was
assumed to be 90 % and coverage for adolescents was
assumed to be 80 %, based on Quebec coverage rates
[38, 43]. The conjugate C and the MCV-4 vaccines
were assumed to be 97 % efficacious in protecting inoc-
ulated individuals, while the B vaccine was assumed to
be 64 % efficacious [44].
Vaccination operates in an “all-or-none” fashion, such
that individuals who are efficaciously vaccinated receive
full protection from infection and cannot transmit in-
fection to others, while individuals who are not effica-
ciously vaccinated receive no protection and remain
susceptible. Individuals are only protected against ser-
ogroups included in the vaccine (i.e., none of the vaccines,
including 4CMenB, confer cross-immunity). Individuals
are randomly selected each month to be vaccinated ac-
cording to the vaccine coverage for their age group, and
each vaccinated person is protected with a probability
equal to the vaccine efficacy.
Table 1 Vaccine Scenarios for the 4-strain model
4-strain Vaccine Scenarios
Age of Immunization Vaccine Type Efficacy Coverage
1 12 months C 97 % 90 %
2 12 years C 97 % 80 %
3 12 months and 12 years C 97 % 90 %/80 %
4 12 months MCV-4 97 % 90 %
5 12 years MCV-4 97 % 80 %
6 12 months and 12 years MCV-4 97 % 90 %/80 %
7 12 months 4CMenB 64 % 90 %
8 12 years 4CMenB 64 % 80 %
9 12 months and 12 years 4CMenB 64 % 90 %/80 %
The efficacy of the conjugate C vaccine and the MCV-4 vaccine are assumed
to be 97 % [41, 46]. The 4CMenB vaccine efficacy is assumed to be 64 % based
on [44]. The duration of vaccine protection is assumed to be 4 years
Table 2 Vaccine scenarios for the 2-strain model
2-strain Vaccine Scenarios
Age of Immunization Vaccine Type Efficacy Coverage
10 12 months C 97 % 90 %
11 12 years C 97 % 80 %
12 12 months and 12 years C 97 % 90 %/80 %
13 12 months 4CMenB 64 % 90 %
14 12 years 4CMenB 64 % 80 %
15 12 months and 12 years 4CMenB 64 % 90 %/80 %
The efficacy of the conjugate C vaccine is 97 % [46]. The 4CMenB vaccine
efficacy is assumed to be 64 % based on [44]. The duration of vaccine
protection is assumed to be 4 years
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Table 3 Reduction in prevalence of carriage with the Conjugate C vaccine
Vaccine Program Model Type Serogroup t = 149 t = 160 t = 175 t = 190 Relative Change
1 2-strain model C 0.005 0.003 0.000 0.000 −0.760
(0.012) (0.007) (0.000) (0.000) (0.427)
Other 0.109 0.108 0.107 0.108 −0.009
(0.008) (0.008) (0.010) (0.009) (0.054)
Total 0.115 0.111 0.107 0.108 −0.050
(0.020) (0.015) (0.011) (0.009) (0.068)
4-strain model B 0.031 0.030 0.031 0.031 0.014
(0.013) (0.010) (0.012) (0.014) (0.276)
C 0.013 0.008 0.000 0.000 −0.960
(0.012) (0.008) (0.001) (0.000) (0.196)
Other 0.045 0.047 0.050 0.050 0.357
(0.028) (0.026) (0.021) (0.022) (0.860)
Nl 0.025 0.025 0.025 0.025 −0.011
(0.003) (0.002) (0.002) (0.004) (0.082)
Total 0.114 0.110 0.106 0.106 −0.070
(0.056) (0.047) (0.036) (0.039) (0.102)
2 2-strain model C 0.006 0.002 0.000 0.000 −0.840
(0.011) (0.004) (0.000) (0.000) (0.367)
Other 0.108 0.110 0.108 0.107 −0.007
(0.011) (0.009) (0.009) (0.009) (0.058)
Total 0.114 0.112 0.108 0.107 −0.053
(0.022) (0.013) (0.010) (0.009) (0.073)
4-strain model B 0.031 0.031 0.031 0.032 0.064
(0.015) (0.012) (0.013) (0.012) (0.259)
C 0.015 0.006 0.000 0.000 −1.00
(0.014) (0.006) (0.001) (0.000) (0.000)
Other 0.047 0.050 0.051 0.052 0.412
(0.030) (0.027) (0.022) (0.020) (1.643)
Nl 0.026 0.025 0.025 0.025 −0.014
(0.003) (0.002) (0.003) (0.003) (0.078)
Total 0.118 0.112 0.107 0.108 −0.076
(0.061) (0.047) (0.038) (0.035) (0.097)
3 2-strain model C 0.007 0.001 0.000 0.000 −0.840
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Table 3 Reduction in prevalence of carriage with the Conjugate C vaccine (Continued)
(0.012) (0.002) (0.000) (0.000) (0.367)
Other 0.109 0.110 0.108 0.108 −0.007
(0.011) (0.030) (0.010) (0.010) (0.060)
Total 0.116 0.111 0.108 0.108 −0.063
(0.022) (0.032) (0.010) (0.010) (0.087)
4-strain model B 0.031 0.034 0.032 0.031 0.064
(0.015) (0.017) (0.016) (0.013) (0.259)
C 0.014 0.004 0.000 0.000 −1.00
(0.010) (0.007) (0.001) (0.000) (0.000)
Other 0.046 0.044 0.048 0.052 0.412
(0.024) (0.027) (0.022) (0.020) (−0.004)
Nl 0.025 0.025 0.025 0.025 −0.014
(0.002) (0.003) (0.002) (0.003) (0.078)
Total 0.115 0.108 0.105 0.108 −0.061
(0.052) (0.054) (0.040) (0.036) (0.103)
Reduction in the prevalence of carriage when an immunization program with the Conjugate C Vaccine is scheduled at 12 month (program 1), 12 years (program 2), and both 12 months and 12 years (program 3)
beginning at t = 150 years. Results for both 2-strain and 4-strain models are shown
Poore
and
Bauch
BM
C
Infectious
D
iseases
 (2015) 15:300 
Page
6
of
14
Results
The overall prevalence of carriage decreases with the intro-
duction of vaccination, regardless of the serogroup targeted
by the vaccine or the age of immunization (Tables 3, 4, 5).
Herd immunity was also observed for every vaccine sce-
nario, since prevalence declined in age groups not targeted
by the vaccine. We compare the 2-strain and 4-strain
model predictions for each vaccine type in the following
subsections.
C Vaccine
In the 4-strain model, introducing the C vaccine causes
the prevalence of serogroup C to decline quickly
(Fig. 1a-c, see also Additional file 1: Figure S3a-c for
time series plots with standard deviation bars on model
outputs). The 2-strain model sees a more rapid reduc-
tion in the prevalence of carriage for serogroup C
(Fig. 1d-f, see also Additional file 1: Figure S3d-f ). In the
2-strain model, serogroup C prevalence is reduced to
almost zero by approximately t = 165 years, while in the
4-strain model this occurs by approximately t = 170
years. After 15 years, the prevalence of carriage is re-
duced by 88.1 %, 95.0 %, and 97.3 % for the 4-strain
model, compared to 96.3 %, 96.1 %, and 99.9 % for the
2-strain model, for vaccine programs 1–3 respectively
(p = 0.0002, 0.0008, and 0.0001, respectively) (Table 3).
The 4-strain model predicts slight strain replacement
caused by the C vaccine: the prevalence of “Other”
Table 4 Reduction in prevalence of carriage with the MVC-4 vaccine
Vaccine Program Model Type Serogroup t = 149 t = 160 t = 175 t = 190 Relative Change
4 4-strain model B 0.031 0.031 0.035 0.036 0.202
(0.014) (0.013) (0.013) (0.010) (0.259)
C 0.015 0.011 0.001 0.000 −0.958
(0.013) (0.009) (0.001) (0.000) (0.198)
Other 0.045 0.037 0.011 0.001 −0.974
(0.026) (0.022) (0.010) (0.003) (0.052)
Nl 0.025 0.024 0.023 0.022 −0.118
(0.003) (0.002) (0.002) (0.003) (0.080)
Total 0.117 0.102 0.070 0.059 −0.492
(0.056) (0.047) (0.027) (0.017) (0.060)
5 4-strain model B 0.030 0.032 0.035 0.035 0.206
(0.014) (0.015) (0.016) (0.017) (0.275)
C 0.013 0.006 0.000 0.000 −0.920
(0.015) (0.008) (0.002) (0.000) (0.271)
Other 0.046 0.031 0.008 0.000 −0.971
(0.028) (0.020) (0.009) (0.001) (0.139)
Nl 0.026 0.024 0.023 0.023 −0.106
(0.007) (0.003) (0.002) (0.005) (0.135)
Total 0.115 0.093 0.067 0.059 −0.487
(0.064) (0.046) (0.029) (0.023) (0.087)
6 4-strain model B 0.029 0.031 0.033 0.034 0.244
(0.019) (0.017) (0.019) (0.020) (0.352)
C 0.016 0.017 0.000 0.000 −0.960
(0.019) (0.009) (0.000) (0.000) (0.196)
Other 0.043 0.021 0.003 0.000 −0.957
(0.034) (0.017) (0.005) (0.000) (0.196)
Nl 0.025 0.024 0.022 0.022 −0.121
(0.004) (0.002) (0.003) (0.002) (0.066)
Total 0.113 0.082 0.059 0.057 −0.499
(0.075) (0.045) (0.028) (0.023) (0.090)
Reduction in the prevalence of carriage when an immunization program with the quadrivalent MCV-4 vaccine is scheduled for 12 month (program 4), 12 year
(program 5), and 12 months and 12 years (program 9) beginning at t = 150 years. Results for the 4-strain model are shown
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Table 5 Reduction in prevalence of carriage with the 4CMenB vaccine
Vaccine Program Model Type Serogroup t = 149 t = 160 t = 175 t = 190 Relative Change
7 2-strain model B 0.027 0.021 0.008 0.000 −0.996
(0.010) (0.008) (0.005) (0.000) (0.006)
Other 0.109 0.109 0.107 0.107 −0.017
(0.009) (0.007) (0.007) (0.009) (0.056)
Total 0.136 0.131 0.115 0.107 −0.209
(0.019) (0.015) (0.012) (0.009) (0.052)
4-strain model B 0.031 0.030 0.022 0.004 −0.861
(0.014) (0.023) (0.015) (0.014) (0.000)
C 0.016 0.016 0.019 0.026 0.665
(0.014) (0.013) (0.015) (0.021) (0.007)
Other 0.046 0.039 0.015 0.028 −0.394
(0.028) (0.046) (0.032) (0.054) (0.026)
Nl 0.026 0.025 0.023 0.024 −0.083
(0.003) (0.004) (0.003) (0.004) (0.001)
Total 0.119 0.109 0.079 0.082 −0.308
(0.059) (0.086) (0.066) (0.093) (0.240)
8 2-strain model B 0.027 0.015 0.004 0.000 −0.995
(0.007) (0.006) (0.006) (0.000) (−0.006)
Other 0.110 0.109 0.107 0.108 −0.016
(0.006) (0.010) (0.011) (0.010) (0.004)
Total 0.137 0.124 0.111 0.108 −0.210
(0.012) (0.016) (0.016) (0.010) (0.048)
4-strain model B 0.033 0.025 0.016 0.003 −0.900
(0.016) (0.019) (0.018) (0.013) (0.003)
C 0.015 0.019 0.023 0.030 0.931
(0.020) (0.022) (0.024) (0.029) (0.009)
Other 0.044 0.021 0.014 0.024 −0.444
(0.027) (0.032) (0.029) (0.038) (0.011)
Nl 0.026 0.024 0.023 0.024 −0.075
(0.002) (0.004) (0.003) (0.003) (0.001)
Total 0.117 0.089 0.076 0.081 −0.317
(0.065) (0.077) (0.074) (0.083) (0.195)
9 2-strain model B 0.027 0.013 0.001 0.000 −0.027
(0.010) (0.007) (0.002) (0.000) (0.010)
Other 0.109 0.110 0.107 0.107 −0.999
(0.010) (0.008) (0.008) (0.009) (−0.001)
Total 0.135 0.123 0.108 0.107 −0.206
(0.020) (0.015) (0.011) (0.009) (0.057)
4-strain model B 0.031 0.025 0.009 0.003 −0.905
(0.019) (0.020) (0.018) (0.013) (−0.006)
C 0.014 0.016 0.023 0.024 0.736
(0.017) (0.020) (0.025) (0.023) (0.006)
Other 0.042 0.022 0.015 0.027 −0.364
(0.035) (0.038) (0.039) (0.048) (0.013)
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increases slightly while the prevalence of Nl and B re-
main constant in vaccine programs 2 and 3, whereas the
2-strain model shows very little evidence of strain re-
placement, on account of the significant difference in
prevalence between serogroup C and “Other”, which in-
cludes the very common species Neisseria lactamica.
This has implications for disease control since different
serogroups cause differing pathogenicity.
MCV-4 Vaccine
Vaccine programs 4 to 6 introduced a quadrivalent
ACWY vaccine. In the 4-strain model, this reduced
serogroup C as well as the “other” serogroup which
partially includes A, W-135 and Y. Similar to the
monovalent C vaccine, it takes about 20 years to reduce
the prevalence of carriage serogroup C to almost zero.
However, it requires an additional 10 years for the “other”
serogroup to be reduced to the same level (Fig. 2a-c, see
also Additional file 1: Figure S4a-c). The overall reduction
in Nm prevalence was greater than for the C vaccine, on
account of the MCV-4 vaccine including more ser-
ogroups. The MCV-4 vaccine causes strain replacement
of serogroup B, but not of Nl, which is least affected by
competition because it has a different duration of carriage
than is typical for Nm serogroups.
In the 4-strain model, the MCV-4 vaccine programs
reduced the overall prevalence of carriage by 49.2 %,
48.7 %, and 49.9 % after 40 years, compared to the re-
duction of 7.0 %, 7.6 %, and 6.1 % under the C vaccine,
for vaccine programs 1–3 respectively (p = <0.0001,
<0.0001, and <0.0001, respectively) (Table 4). The reduc-
tion in overall prevalence of carriage is higher for the
Table 5 Reduction in prevalence of carriage with the 4CMenB vaccine (Continued)
Nl 0.025 0.023 0.023 0.024 −0.060
(0.003) (0.003) (0.004) (0.024) (0.002)
Total 0.112 0.085 0.070 0.078 −0.302
(0.075) (0.082) (0.085) (0.089) (0.264)
Reduction in the prevalence of carriage when an immunization program with the 4CMenB vaccine is scheduled for 12 month (program 7), 12 years (program 8),
and both 12 months and 12 years (program 9) beginning at t = 150 years. Results for both 2-strain and 4-strain models are shown
a b c
d e f
g h i
Fig. 1 Prevalence of carriage with C vaccine. The prevalence of carriage under vaccine programs 1 (a,d,g), 2 (b,e,h) and 3 (c,f,i) for the 4-strain
model (a-c, showing “C”, “B”, “Nl”, and “Other”), the 2-strain model (d-f, showing “C” and “Other”), and an overlay of model outputs for both
models (g-i, showing “C” and “Other”). The initial carriage prevalence of serogroup C is different in the 2-strain and 4-strain models because of
the filtering procedure used during model parameterization. The same plot with standard deviations of model outputs appears in Additional file
1: Figure S3
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MCV-4 vaccine owing to its greater serogroup coverage
than the C vaccine.
4CMenB vaccine
According to the 4-strain model, 4CMenB vaccine
causes the prevalence of carriage to decline at a much
slower rate than the decline in serogroups C and “Other”
when C and MCV-4 vaccines were introduced. This dif-
ference is on account of the lower vaccine efficacy of
4CMenB (Fig. 3a-c, see also Additional file 1: Figure
S5a-c). However, as was the case for the C and MCV-4
vaccines, the prevalence of serogroup B drops very close
to zero after a sufficient amount of time.
In the 4-strain model, due to the high prevalence of
serogroup B, the prevalence of serogroup C increases
significantly when the 4CMenB vaccine is introduced on
account of strain replacement, growing to a level com-
parable to that exhibited by serogroup B before the vac-
cine was introduced to the population (Fig. 3a-c, see also
Additional file 1: Figure S5a-c). More interestingly, for
vaccine programs 7 and 8, the prevalence of “Other” at
first declines along with the prevalence of B, but then re-
bounds, and for vaccine program 9, the prevalence of
“Other” declines steeply and remains low. This suggests
that changes in the prevalence of serogroup B may be
pushing the prevalence of “Other” to a basin of attrac-
tion for an alternative stable state (see next subsection).
We also point out that any changes in serogroup C
prevalence (caused by vaccine-induced changes to ser-
ogroup B prevalence) would also have additional impacts
on “Other” serogroup prevalence, and hence the out-
comes can be more complicated than would be observed
with a fewer-strain model.
The 2-strain model also predicted a slower decline
under the 4CMenB vaccine compared to the declines
under the C and MCV-4 vaccine (Fig. 3d-f, see also
Additional file 1: Figure S5d-f ). However, as was ob-
served with the C vaccine, the predicted decline in ser-
ogroup B under the 4CMenB vaccine is significantly
faster under the 2-strain model than the 4-strain model
(see also Fig. 3g-i, Additional file 1: Figure S5g-i). After
30 years of immunization, the 4-strain model predicts a
reduction of 65.8 %, 61.7 % and 72.4 % in serogroup B
for vaccine programs 7–9 respectively while the 2-strain
model predicts a reduction of 93.4 %, 93.7 % and 98.5 %
in serogroup B for vaccine programs 7–9 respectively,
over the same 30-year time period (p = <0.0001, <0.0001,
and <0.0001, respectively) (Table 5). Both 2-strain and
4-strain models predict that vaccinating at 12 months
and 12 years of age causes the most rapid declines in
prevalence (Table 5).
Unlike the 4-strain model, the 2-strain model predicts
no strain replacement, which we again speculate is due
to the much higher prevalence of the aggregated “Other”
category, which includes Neisseria lactamica.
Apparent multiple attractors
During calibration of the 4-strain model it was noted
that some parameter sets gave rise to sustained oscilla-
tions in serogroup prevalence. These were not included
in the foregoing analysis. However, we present a few ex-
amples of these dynamics in Fig. 4. Although all ser-
ogroups oscillate in prevalence to some extent, the
oscillations are particular pronounced for the “Other”
serogroup. The C vaccine (programs 1–3, Fig. 4a-c) re-
duces the prevalence of C without having a significant
impact on the oscillations in the other serogroups. The
MCV-4 vaccine (programs 4–6, Fig. 4d-f ). However, in
some simulations (such as the one depicted in Fig. 4d),
strain interactions drive serogroup B extinct even before
any vaccines are introduced. For the 4CMenB vaccine,
the elimination of serogroup B is accompanied by a shift
in the dynamics of “Other” from sustained oscillations to
Fig. 2 Prevalence of carriage with MCV-4 vaccine. The prevalence of
carriage with vaccine program 4 (a), 5 (b) and 6 (c) for the 4-strain
model. The same plot with standard deviations of model outputs
appears in Additional file 1: Figure S4
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a state of high, stable (non-oscillating) prevalence
(Fig. 4g-i). The prevalence of C also decreases signifi-
cantly, probably in response to competition from a sur-
ging prevalence of “Other”. The dynamics of a 4-strain
model can be rich in ways that cannot be captured with
a 2-strain model. We emphasize that these dynamics re-
sult from an interaction between forcing the system with
the changes induced by the vaccine program, and the
dynamical structure of systems with multiple attractors.
Discussion
Here we developed and compared 2-strain and 4-strain
models of the impacts of several types of vaccines on
Neisseria meningitidis serogroup carriage prevalence.
The 2-strain and 4-strain models predicted similar over-
all impacts of vaccines on carriage prevalence, especially
with respect to the vaccine-targeted serogroups. How-
ever, declines in vaccine-targeted serogroups were more
rapid in the 2-strain model than the 4-strain model, for
both the C and the 4CMenB vaccines.
Also, dynamical interactions that are present in the
4-strain model but not the 2-strain model contributed to
other differences between the models. Sustained oscilla-
tions, and evidence for multiple attractors with differing
basins of attraction, occurred in the 4-strain model but
not the 2-strain model. In the case of the 4CMenB vac-
cine, the decline in serogroup B created an ecological
niche, but because there are more than two other strains
in a 4-strain model, it is not clear a priori whether ser-
ogroup C or “Other” would step in to fill the niche. In
the model simulations, serogorup C was more successful
in filling the niche, and the combined effect of changes
in serogroup C and B prevalence caused the prevalence
of “Other” to at first decrease, and then increase, or sim-
ply to decrease and remain low (Fig. 3d-f ).
Strain replacement was more pronounced in the
4-strain model than the 2-strain model, we speculate on
account of prevalence being more evenly among various
serogroups in the 4-strain model, thus enhancing com-
petitive effects. Neisseria lactamica, owing to its differ-
ent natural history, did not experience the competitive
effects as strongly as other Nm serogroups did from one
another.
Oscillations have potentially important impacts on
model calibration in multi-strain models. In our case, we
excluded parameter sets that yielded oscillations in order
to simplify the analysis. However, there are no empirical
grounds for excluding such parameter sets, and oscilla-
tions in seroprevalence cannot be ruled out based on the
existing and rather limited literature reporting cross-
a
d
g
b
e
h
c
f
i
Fig. 3 Prevalence of carriage with 4CMenB vaccine. The prevalence of carriage with vaccine programs 7 (a,d,g), 8 (b,e,h) and 9 (c,f,i) for the
4-strain model (a-c, showing “C”, “B”, “Nl”, and “Other”), the 2-strain model (d-f, showing “B” and “Other”), and an overlay of model outputs for
both models (g-i, showing “B” and “Other”). The initial carriage prevalence of serogroup “Other” is different in the 2-strain and 4-strain models
because of the filtering procedure used during model parameterization. The same plot with standard deviations of model outputs appears in
Additional file 1: Figure S5
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sectional results from various populations. Future models
should permit oscillatory solutions that satisfy known em-
pirical targets, especially since the qualitative and quanti-
tative impacts of the vaccine could be very different for
oscillatory solutions versus steady state solutions.
These types of dynamics appear exotic but they are
not exclusive to mathematical models. There is evidence
for such dynamics in other infectious disease systems,
such as in pertussis before the introduction of vaccines
[45]. Unfortunately, because high quality longitudinal
data on Nm serogroup carriage prevalence do not exist,
it is difficult to detect these dynamics in the case of
Neisseria meningitidis. Moreover, although IMD is a no-
tifiable disease, it is also highly stochastic, which could
mask the signs of strain replacement on shorter time-
scales [2]. Finally, strain replacement effects can be de-
layed by a number of years, relative to the introduction
of a vaccine program that causes them, and hence may
not be immediately obvious in IMD case notification
time series.
However, as more data on vaccine impacts on IMD inci-
dence and serogroup prevalence become available over
time, such new data can be used to further validate dy-
namic models, which can then be used to evaluate potential
expansions of vaccine programs, or applications to other
populations that do not currently have vaccine programs.
These post-vaccine era data can—and should—be collected
so that mathematical models can better inform policy rec-
ommendations. There is also value in calibrating the same
model to different local circumstances. The additional val-
idation obtained by comparing the model under different
epidemiological, vaccine, and demographic circumstances
can build confidence in the models so that they may better
inform policy. Further work should also explore scenarios
using multiple vaccines, since many jurisdictions are cur-
rently facing the choice of how best to implement vaccin-
ation programs against multiple Nm serogroups.
Conclusions
The phenomena explored in these models may have im-
plications for the predicted effectiveness of Nm vaccin-
ation. Caution should be exercised when determining
which type of model to use to simulate Neisseria menin-
gitis dynamics. Models with few strains are easier to
analyze, but may miss important features of disease
dynamics.
Additional files
Additional file 1: Supplementary Material. Additional file descriptions
text (including details of how to view the file, if it is in a non-standard
format).
a
d
g
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e
h
c
f
i
Fig. 4 Evidence for multiple attractors in the 4-strain model. Examples of simulations from vaccine scenarios 1–9 (a-i) that entered the basin of
attraction for oscillatory solutions. Some oscillations push serogroup prevalence to zero, causing that serogroup to go extinct in the simulation
(no rescue effects were allowed)
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